Ekso Bionics Announces $3.7 Million Registered Direct Offering of Common Stock Priced At-the-Market under Nasdaq Rules

Core Points - Ekso Bionics Holdings, Inc. has entered into a definitive agreement for the purchase and sale of 769,490 shares of common stock at a price of $4.81 per share, expected to close around October 30, 2025 [1] - The gross proceeds from this offering are anticipated to be $3.7 million, which will be used for general corporate purposes including research and development, administrative costs, and working capital needs [3] - The shares are being offered under a "shelf" registration statement previously filed with the SEC, and the offering will be conducted via a prospectus [4] Company Overview - Ekso Bionics is a leading developer of exoskeleton solutions aimed at enhancing human strength, endurance, and mobility for both medical and industrial applications [6] - The company focuses on improving health and quality of life through advanced robotics, and is recognized for its unique technologies that assist individuals with paralysis and enhance capabilities in various job sites [6] - Ekso Bionics is headquartered in the San Francisco Bay Area and is listed on the Nasdaq Capital Market under the symbol "EKSO" [6]